Faes Farma, S.A.

MCE FAE.MC

Faes Farma, S.A. Price to Sales Ratio (P/S) on January 14, 2025: 2.16

Faes Farma, S.A. Price to Sales Ratio (P/S) is 2.16 on January 14, 2025, a 0.41% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Faes Farma, S.A. 52-week high Price to Sales Ratio (P/S) is 2.61 on September 19, 2024, which is 20.87% above the current Price to Sales Ratio (P/S).
  • Faes Farma, S.A. 52-week low Price to Sales Ratio (P/S) is 2.00 on March 14, 2024, which is -7.60% below the current Price to Sales Ratio (P/S).
  • Faes Farma, S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.32.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
MCE: FAE.MC

Faes Farma, S.A.

CEO Mr. Mariano Ucar Angulo
IPO Date Jan. 3, 2000
Location Spain
Headquarters Avenida Autonomía 10
Employees 1,748
Sector Health Care
Industries
Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

Similar companies

VIS.MC

Viscofan, S.A.

USD 61.42

0.44%

EBRO.MC

Ebro Foods, S.A.

USD 16.18

0.35%

VID.MC

Vidrala, S.A.

USD 91.52

-0.29%

ALM.MC

Almirall, S.A.

USD 8.60

3.71%

ENC.MC

ENCE Energía y Celulosa, S.A.

USD 3.25

1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email